Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10
Overview
Authors
Affiliations
Bachmann K, Roumie C, Wiese A, Grijalva C, Buse J, Bradford R Pharmacol Res Perspect. 2020; 8(5):e00637.
PMID: 32881317 PMC: 7507366. DOI: 10.1002/prp2.637.
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Schernthaner G, Karasik A, Abraitiene A, Ametov A, Gaal Z, Gumprecht J Cardiovasc Diabetol. 2019; 18(1):115.
PMID: 31472683 PMC: 6717330. DOI: 10.1186/s12933-019-0920-3.
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?.
Raschi E, Poluzzi E, Fadini G, Marchesini G, De Ponti F Diabetes Obes Metab. 2018; 20(12):2711-2723.
PMID: 30003655 PMC: 6283243. DOI: 10.1111/dom.13468.